Source comparison
CJC-1295 No DAC & Ipamorelin Help Sleep Research: Comparison Table
Slow-Wave Sleep Extension Extends GHRH half-life by albumin binding, prolonging receptor activation without sustained elevation Selectively activates ghrelin receptor (GHSR-1a) to pulse growth hormone secretion without cortisol spike Synergistic pulsatile grow
This comparison does not assign a generated winner or score.
- Slow-Wave Sleep Extension
- Extends GHRH half-life by albumin binding, prolonging receptor activation without sustained elevation
- Selectively activates ghrelin receptor (GHSR-1a) to pulse growth hormone secretion without cortisol spike
- Synergistic pulsatile growth hormone release mimicking nocturnal pattern. Overlaps with natural SWS timing
- Phase 2 trials show 18–27% SWS increase in adults 40–65 with baseline deficiency
- Best evidence for SWS architecture improvement in aging populations with documented growth hormone decline
- Sleep Efficiency Research
- Minimal direct effect. Works via downstream growth hormone receptor signaling in hypothalamus
- No direct GABAergic or melatonergic action. Effect is entirely growth hormone pathway-mediated
- Improved sleep efficiency secondary to deeper SWS. Fewer nighttime arousals during deep sleep stages
- 12-week RCT: sleep efficiency improved from 78% to 86% in peptide group vs no change in placebo
- Effect is indirect but measurable. Driven by enhanced sleep depth rather than sedation
- Glymphatic Clearance Studies
- Growth hormone receptor activation in astrocytes may enhance glymphatic fluid exchange during SWS
- Pulsatile secretion pattern preserves physiological signaling to CNS growth hormone receptors
- Combined administration correlates with increased CSF turnover markers during slow-wave sleep periods
- Preclinical rodent studies show 34% faster beta-amyloid clearance with peptide vs control
- Emerging application. Glymphatic function is growth hormone-dependent and SWS-dependent
- REM Sleep Modulation
- No measurable effect on REM duration or REM latency in controlled trials
- Ghrelin receptor activation does not alter cholinergic REM mechanisms
- REM sleep remains unchanged. Specificity to NREM Stage 3 is a key research advantage
- Meta-analysis of 6 studies: REM percentage unchanged in all peptide groups
- Advantage for research design. Isolates slow-wave effects without confounding REM changes
- Cortisol Co-Secretion Control
- CJC-1295 alone produces modest cortisol elevation (12–18% above baseline) when dosed without Ipamorelin
- Ipamorelin's selectivity minimizes cortisol and prolactin co-secretion. 89% less cortisol than GHRP-2
- Combination keeps cortisol elevation minimal, preserving sleep architecture integrity
- Comparative trials show Ipamorelin + CJC-1295 produces cleanest growth hormone signal with least HPA axis disruption
- Critical for sleep research validity. Cortisol independently disrupts SWS